Abstract
The novel coronavirus SARS-CoV-2 was identified in China in December 2019. With evidence of global spread, it has become a pandemic. At the time of writing, COVID-19, the clinical syndrome caused by SARS-CoV-2, has claimed over 340,653 lives and stretched the capacity of healthcare systems around the world.1 The hallmark of severe COVID-19 is hypoxemic respiratory failure. Management of this condition historically involves procedures that have the potential to generate respiratory aerosols such as non-invasive ventilation and endotracheal intubation. ATS Patient Education Series
Cite
CITATION STYLE
Pasnick, S., Carlos, W. G., Dela Cruz, C. S., Gross, J. E., Garrison, G., & Jamil, S. (2020). SARS-CoV-2 transmission and the risk of aerosol-generating procedures. American Journal of Respiratory and Critical Care Medicine, 202(4), P13–P14. https://doi.org/10.1164/rccm.2024P13
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
